Abstracts tagged "Health Assessment Questionnaire (HAQ)"

Abstract Number: 0187 • ACR Convergence 2022
Patient-reported Outcomes and Quality of Life in Patients with Rheumatoid Arthritis Treated with GP2015: Final Results from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Herbert Kellner³, Rafaela Ortega-Castro⁴, Julio Cesar Vázquez Perez-Coleman⁵, Foti Rosario⁶, Sławomir Jeka⁷, Boulos Haraoui⁸, Yannick Allanore⁹, Masiur Rahman¹⁰, Fabricio Furlan¹⁰, Sohaib Hachaichi¹¹ and Tom Sheeran¹², ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Oswestry, England, United Kingdom, ²University Hospital Wuerzburg, Wuerzburg, Germany, ³Schwerpunktpraxis für Rheumatologie und Gastroenterologie, Munich, Germany, ⁴IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ⁵University Hospital Complex of Ferrol, A Coruña, Spain, ⁶Policlinico G. Rodolico-S.Marco Hospital, Catania, Italy, ⁷University Hospital No 2 in Bydgoszcz Collegium Medicum UMK, Clinic and Department of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁸Institut de rhumatologie de Montréal, Montréal, QC, Canada, ⁹Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, ¹⁰Sandoz Hexal AG, Holzkirchen, Germany, ¹¹Hexal AG (A Sandoz company), Holzkirchen, Germany, ¹²New Cross and Cannock Chase Hospitals, University of Wolverhampton, Cannock, United Kingdom
Background/Purpose: COMPACT is a non-interventional study evaluating the persistence, effectiveness, safety and patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA), axial-spondyloarthritis or psoriatic arthritis…
Abstract Number: 0243 • ACR Convergence 2022
Real World Evidence of Treatment Effectiveness and Unfavorable Clinical Events for Elderly-onset Early Rheumatoid Arthritis in Japan: Results from the IORRA Study
Naohiro Sugitani¹, Eiichi Tanaka¹, Eisuke Inoue², Kotaro Watanabe³, Mai Abe³, Eri Sugano³, Kumiko Saka³, Moeko Ochiai³, Rei Yamaguchi³, Katsunori Ikari⁴ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Research Administration Center, Showa University, Shinagawa-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Japan, ⁴Department of Orthopedic Surgery, Tokyo Women’s Medial University School of Medicine, Shinjuku, Japan
Background/Purpose: The number of elderly patients with rheumatoid arthritis (RA) has been constantly increasing. As of December 2021, 50.3% of the patients with RA who…
Abstract Number: 0313 • ACR Convergence 2022
Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of Rheumatoid Arthritis (RA). In these analyses, we present patient reported outcomes (PROs) reported by MTX-IR patients…
Abstract Number: 0314 • ACR Convergence 2022
Olokizumab Improved Patient Reported Outcomes in TNF Incomplete Responder (TNF-IR) Rheumatoid Arthritis Patients: Results from the Phase III Randomized Controlled Trial
Vibeke Strand¹, Evgeny Nasonov², Tatiana Lisitsyna², Alexander Lila², Sofia Kuzkina³, Mikhail Samsonov⁴ and Eugen Feist⁵, ¹Stanford University School of Medicine, Stanford, CA, ²V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, ³R-Pharm, Moscow, Russia, ⁴R-Pharm JSC, Moscow, Russia, ⁵Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Magdeburg, Germany
Background/Purpose: Olokizumab (OKZ) is an interleukin-6-inhibitor for treatment of rheumatoid arthritis (RA). In these analyses we present patient reported outcomes (PROs) reported by TNF-IR patients…
Abstract Number: 0437 • ACR Convergence 2022
Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Rula Hajj-Ali¹, Carol Langford², Chao Zhang², Leonard Calabrese², David Cuthbertson³, Nader Khalidi⁴, Curry Koening⁵, Carol McAlear⁶, Paul Monach⁷, Larry Moreland⁸, Christian Pagnoux⁹, Ulrich Specks¹⁰, Antoine Sreih¹¹, Kenneth J. Warrington¹⁰ and Peter Merkel¹², ¹Cleveland Clinic, Hunting Valley, OH, ²Cleveland Clinic, Cleveland, OH, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA, ⁷VA Boston Healthcare System, Boston, MA, ⁸University of Colorado, Denver, CO, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Mayo Clinic, Rochester, MN, ¹¹Bristol Myers Squibb, Philadelphia, PA, ¹²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neurologic involvement (NI) in ANCA-associated vasculitis (AAV) is common, occurring in approximately one-third of patients, and leads to significant and often chronic functional limitations…
Abstract Number: 0699 • ACR Convergence 2022
Effectiveness by Disease Severity in Patients with Psoriatic Arthritis Treated with Apremilast in the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Jacqueline O'Brien², Wendi Malley², Elizabeth Kohl², Kate Orroth³, Yuri Klyachkin⁴, Myriam Cordey⁵ and Philip J Mease⁶, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Amgen, Manhattan Beach, CA, ⁴Amgen, Lexington, KY, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: Clinical trials of the efficacy and safety of apremilast have shown a significant therapeutic effect on disease activity across clinically diverse PsA patients. Given…
Abstract Number: 0891 • ACR Convergence 2022
Rheumatoid Arthritis and the Rheumatic Disease Comorbidity Index (RDCI): Its Impact on Disease Activity
Sultana Abdulaziz¹, Suzan Attar², Renad Ahmed², Hamza Fida², Omar Bokhary², Anas Alyazidi² and Abdulelah Abumohssin², ¹King Fahad Hospital, Jeddah, Saudi Arabia, ²King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: Comorbid conditions in the setting of rheumatoid arthritis (RA) play an important role in predicting disease activity and functional impairment (1). Application of a…
Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Mike Putman¹, David Gazeley² and Ikechukwu Mbonu³, ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…
Abstract Number: 2243 • ACR Convergence 2022
Patient Reported Outcomes from a Randomized Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica
Vibeke Strand¹, Jennifer Sloane Lazar², Michael C Nivens³, Jingdong Chao⁴, Stefano Fiore⁵, Angeliki Giannelou⁶, Lita Araujo⁷ and Jerome Msihid⁸, ¹Stanford University School of Medicine, Stanford, CA, ²Sanofi, Delray Beach, FL, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁴Regeneron Pharmaceuticals, Inc.,, Tarrytown, NY, ⁵Sanofi, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Hoboken, NJ, ⁷Sanofi, Cambridge, MA, ⁸Sanofi, Chilly-Mazarin, France
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory rheumatic disease in the elderly. The phase 3 SAPHYR trial (NCT03600818) assessed the efficacy and safety of…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
Abstract Number: 1266 • ACR Convergence 2021
Quality of Life Measures and Physical Activity in Childhood Systemic Lupus Erythematosus
Meghan Nelson¹, Lori Ponder², Sinclair Gibson³, D. Sofia Villacis- Nunez¹, Lai Hin Kimi Chan³, Lakshmi Moorthy⁴ and Sampath Prahalad⁵, ¹Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, ²Children's Healthcare of Atlanta, Atlanta, GA, ³Children’s Healthcare of Atlanta, Atlanta, GA, ⁴Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Childhood systemic lupus erythematosus (cSLE) is a life-long disease with significant morbidity and mortality, and with associated significant impact on health-related quality of life…
Abstract Number: 1777 • ACR Convergence 2021
Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis
Alexis Ogdie-Beatty¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Jason Shafrin³, Sofia Pedro⁴, Esther Yi⁵, Steven Hass⁶ and Kaleb Michaud⁷, ¹University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, CA, ⁴Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ⁵Novartis Pharmaceuticals Corporation, Weehawken, NJ, ⁶H.E. Outcomes, LLC, Los Angeles, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with psoriatic arthritis (PsA) or ankylosing spondylitis (AS) experience chronic pain due to inflammatory attributes of their disease. Nonsteroidal anti‑inflammatory drugs and biologics…
Abstract Number: 0809 • ACR Convergence 2021
The Impact of Flares on Clinical and Patient Reported Outcomes in Rheumatoid and Undifferentiated Arthritis Patients
Johanna Maria Maassen¹, Sytske Anne Bergstra¹, PDM de Buck², Maikel van Oosterhout³, Cornelia F. Allaart¹ and Tom WJ Huizinga¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Haaglanden medical center, The Hague, Netherlands, ³Groene Hart Hospital, Gouda, Netherlands
Background/Purpose: There are many definitions of flare in rheumatoid arthritis (RA). Loss of low disease activity is associated with clinically relevant deterioration. Patients in DAS…
Abstract Number: 0025 • ACR Convergence 2020
Clinical and Psychological Assessment of Rheumatoid Arthritis Patients with Fibromyalgia: A Real World Study
Tian Liu¹, Chao Gao¹ and Lihong Chen¹, ¹hospital, Beijing, China (People's Republic)
Background/Purpose: To assess the clinical features and psychological status of the rheumatoid arthritis(RA) patients with fibromyalgia(FM) in a real-world observational setting.Methods: Between December 2018 to…
Abstract Number: 0136 • ACR Convergence 2020
Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies
Clifton Bingham III¹, David Walker², Peter Nash³, Susan Lee⁴, Lei Ye⁴, Hao Hu⁴, Javaria Mona Khalid⁵ and Bernard Combe⁶, ¹Johns Hopkins University, Baltimore, MD, ²Northumbria Healthcare NHS Foundation Trust, North Shields, United Kingdom, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos BV, Leiden, Netherlands, ⁶University of Montpellier, Montpellier, France
Background/Purpose: Reduction in pain and fatigue, maintenance of physical functioning, and improvement in health-related quality of life (HRQoL) are vital aspects of successful treatment for…